Policy | August 27, 2025
Indian pharma resilient to US tariffs; Eyes US pricing reform gains: Ind-Ra
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
Mangalam Drugs and Organics receives repeat export order worth $ 21, 81,040
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Subscribe To Our Newsletter & Stay Updated
